London, United Kingdom – May 11, 2023 – Ascend Gene & Cell Therapies, a biotechnology research company specializing in providing manufacturing capacity for gene and cell therapy developers, today announced the successful completion of its Series A funding round, raising $132.5 million.

The funding round was led by Digitalis Ventures, Abingworth, Cathay Health, Monograph Capital, DCVC Bio, Deerfield Management, Petrichor Healthcare Capital Management, and 4BIO Capital. The investment will be used to expand the company’s manufacturing and analytical capabilities and to develop its clinical manufacturing and regulatory support services.

Founded by Mike Stella, Ascend Gene & Cell Therapies provides flexible chemistry, manufacturing, and controls (CMC) services to biotech companies working in advanced modalities. The company’s team of approximately 120 cross-functional experts in the UK, Germany, and the United States is dedicated to creating the most effective, highest-quality, and scalable gene therapies possible.

“We are delighted to have secured this funding round, which will allow us to continue to develop our manufacturing and analytical capabilities and expand our clinical manufacturing and regulatory support services,” said Mike Stella, Founder of Ascend Gene & Cell Therapies. “Our mission is to provide quality manufacturing capacity for any gene and cell therapy developer, and this investment will help us to achieve our goal of creating the most effective and highest-quality gene therapies possible.”